The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia

Jean Charles Fruchart, Frank Sacks, Michel P. Hermans, Gerd Assmann, W. Virgil Brown, Richard Ceska, M. John Chapman, Paul M. Dodson, Paola Fioretto, Henry N. Ginsberg, Takashi Kadowaki, Jean Marc Lablanche, Nikolaus Marx, Jorge Plutzky, Željko Reiner, Robert S. Rosenson, Bart Staels, Jane K. Stock, Rody Sy, Christoph Wanner & 2 others Alberto Zambon, Paul Zimmet

Research output: Contribution to journalArticle

305 Citations (Scopus)

Abstract

Despite achieving targets for low-density lipoprotein (LDL) cholesterol, blood pressure, and glycemia in accordance with current standards of care, patients with dyslipidemia remain at high residual risk of vascular events. Atherogenic dyslipidemia, characterized by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol, often with elevated apolipoprotein B and non-HDL cholesterol, is common in patients with established cardiovascular disease (CVD), type 2 diabetes mellitus, or metabolic syndrome and contributes to both macrovascular and microvascular residual risk. However, atherogenic dyslipidemia is largely underdiagnosed and undertreated in clinical practice. The Residual Risk Reduction Initiative (R3i) was established to address this highly relevant clinical issue. The aims of this position paper are (1) to highlight evidence that atherogenic dyslipidemia is associated with residual macrovascular and microvascular risk in patients at high risk for CVD, despite current standards of care for dyslipidemia and diabetes; and (2) to recommend therapeutic intervention for reducing this residual vascular risk supported by evidence and expert consensus. Lifestyle modification with nutrition and exercise is an important, effective, and underutilized first step in reducing residual vascular risk. Therapeutic intervention aimed at achievement of all lipid targets is also often required. Combination lipid-modifying therapy, with the addition of niacin, a fibrate, or omega-3 fatty acids to statin therapy, increases the probability of achieving all lipid goals. Outcomes studies are in progress to evaluate whether these combination treatment strategies translate to a clinical benefit greater than that achieved with statins alone. The R3i highlights the need to address with lifestyle and/or pharmacotherapy the high level of residual risk of CVD events and microvascular complications among patients with dyslipidemia receiving therapy for high levels of LDL cholesterol and for diabetes in accordance with current standards of care.

LanguageEnglish
Pages1K-34K
JournalAmerican Journal of Cardiology
Volume102
Issue number10 SUPPL.
DOIs
Publication statusPublished - 17 Nov 2008

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Fruchart, J. C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., ... Zimmet, P. (2008). The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. American Journal of Cardiology, 102(10 SUPPL.), 1K-34K. https://doi.org/10.1016/j.amjcard.2008.10.002
Fruchart, Jean Charles ; Sacks, Frank ; Hermans, Michel P. ; Assmann, Gerd ; Brown, W. Virgil ; Ceska, Richard ; Chapman, M. John ; Dodson, Paul M. ; Fioretto, Paola ; Ginsberg, Henry N. ; Kadowaki, Takashi ; Lablanche, Jean Marc ; Marx, Nikolaus ; Plutzky, Jorge ; Reiner, Željko ; Rosenson, Robert S. ; Staels, Bart ; Stock, Jane K. ; Sy, Rody ; Wanner, Christoph ; Zambon, Alberto ; Zimmet, Paul. / The Residual Risk Reduction Initiative : A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. In: American Journal of Cardiology. 2008 ; Vol. 102, No. 10 SUPPL. pp. 1K-34K.
@article{6caac2d5d6c84ab4b612b44092b07468,
title = "The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia",
abstract = "Despite achieving targets for low-density lipoprotein (LDL) cholesterol, blood pressure, and glycemia in accordance with current standards of care, patients with dyslipidemia remain at high residual risk of vascular events. Atherogenic dyslipidemia, characterized by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol, often with elevated apolipoprotein B and non-HDL cholesterol, is common in patients with established cardiovascular disease (CVD), type 2 diabetes mellitus, or metabolic syndrome and contributes to both macrovascular and microvascular residual risk. However, atherogenic dyslipidemia is largely underdiagnosed and undertreated in clinical practice. The Residual Risk Reduction Initiative (R3i) was established to address this highly relevant clinical issue. The aims of this position paper are (1) to highlight evidence that atherogenic dyslipidemia is associated with residual macrovascular and microvascular risk in patients at high risk for CVD, despite current standards of care for dyslipidemia and diabetes; and (2) to recommend therapeutic intervention for reducing this residual vascular risk supported by evidence and expert consensus. Lifestyle modification with nutrition and exercise is an important, effective, and underutilized first step in reducing residual vascular risk. Therapeutic intervention aimed at achievement of all lipid targets is also often required. Combination lipid-modifying therapy, with the addition of niacin, a fibrate, or omega-3 fatty acids to statin therapy, increases the probability of achieving all lipid goals. Outcomes studies are in progress to evaluate whether these combination treatment strategies translate to a clinical benefit greater than that achieved with statins alone. The R3i highlights the need to address with lifestyle and/or pharmacotherapy the high level of residual risk of CVD events and microvascular complications among patients with dyslipidemia receiving therapy for high levels of LDL cholesterol and for diabetes in accordance with current standards of care.",
author = "Fruchart, {Jean Charles} and Frank Sacks and Hermans, {Michel P.} and Gerd Assmann and Brown, {W. Virgil} and Richard Ceska and Chapman, {M. John} and Dodson, {Paul M.} and Paola Fioretto and Ginsberg, {Henry N.} and Takashi Kadowaki and Lablanche, {Jean Marc} and Nikolaus Marx and Jorge Plutzky and Željko Reiner and Rosenson, {Robert S.} and Bart Staels and Stock, {Jane K.} and Rody Sy and Christoph Wanner and Alberto Zambon and Paul Zimmet",
year = "2008",
month = "11",
day = "17",
doi = "10.1016/j.amjcard.2008.10.002",
language = "English",
volume = "102",
pages = "1K--34K",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "10 SUPPL.",

}

Fruchart, JC, Sacks, F, Hermans, MP, Assmann, G, Brown, WV, Ceska, R, Chapman, MJ, Dodson, PM, Fioretto, P, Ginsberg, HN, Kadowaki, T, Lablanche, JM, Marx, N, Plutzky, J, Reiner, Ž, Rosenson, RS, Staels, B, Stock, JK, Sy, R, Wanner, C, Zambon, A & Zimmet, P 2008, 'The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia', American Journal of Cardiology, vol. 102, no. 10 SUPPL., pp. 1K-34K. https://doi.org/10.1016/j.amjcard.2008.10.002

The Residual Risk Reduction Initiative : A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. / Fruchart, Jean Charles; Sacks, Frank; Hermans, Michel P.; Assmann, Gerd; Brown, W. Virgil; Ceska, Richard; Chapman, M. John; Dodson, Paul M.; Fioretto, Paola; Ginsberg, Henry N.; Kadowaki, Takashi; Lablanche, Jean Marc; Marx, Nikolaus; Plutzky, Jorge; Reiner, Željko; Rosenson, Robert S.; Staels, Bart; Stock, Jane K.; Sy, Rody; Wanner, Christoph; Zambon, Alberto; Zimmet, Paul.

In: American Journal of Cardiology, Vol. 102, No. 10 SUPPL., 17.11.2008, p. 1K-34K.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Residual Risk Reduction Initiative

T2 - American Journal of Cardiology

AU - Fruchart, Jean Charles

AU - Sacks, Frank

AU - Hermans, Michel P.

AU - Assmann, Gerd

AU - Brown, W. Virgil

AU - Ceska, Richard

AU - Chapman, M. John

AU - Dodson, Paul M.

AU - Fioretto, Paola

AU - Ginsberg, Henry N.

AU - Kadowaki, Takashi

AU - Lablanche, Jean Marc

AU - Marx, Nikolaus

AU - Plutzky, Jorge

AU - Reiner, Željko

AU - Rosenson, Robert S.

AU - Staels, Bart

AU - Stock, Jane K.

AU - Sy, Rody

AU - Wanner, Christoph

AU - Zambon, Alberto

AU - Zimmet, Paul

PY - 2008/11/17

Y1 - 2008/11/17

N2 - Despite achieving targets for low-density lipoprotein (LDL) cholesterol, blood pressure, and glycemia in accordance with current standards of care, patients with dyslipidemia remain at high residual risk of vascular events. Atherogenic dyslipidemia, characterized by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol, often with elevated apolipoprotein B and non-HDL cholesterol, is common in patients with established cardiovascular disease (CVD), type 2 diabetes mellitus, or metabolic syndrome and contributes to both macrovascular and microvascular residual risk. However, atherogenic dyslipidemia is largely underdiagnosed and undertreated in clinical practice. The Residual Risk Reduction Initiative (R3i) was established to address this highly relevant clinical issue. The aims of this position paper are (1) to highlight evidence that atherogenic dyslipidemia is associated with residual macrovascular and microvascular risk in patients at high risk for CVD, despite current standards of care for dyslipidemia and diabetes; and (2) to recommend therapeutic intervention for reducing this residual vascular risk supported by evidence and expert consensus. Lifestyle modification with nutrition and exercise is an important, effective, and underutilized first step in reducing residual vascular risk. Therapeutic intervention aimed at achievement of all lipid targets is also often required. Combination lipid-modifying therapy, with the addition of niacin, a fibrate, or omega-3 fatty acids to statin therapy, increases the probability of achieving all lipid goals. Outcomes studies are in progress to evaluate whether these combination treatment strategies translate to a clinical benefit greater than that achieved with statins alone. The R3i highlights the need to address with lifestyle and/or pharmacotherapy the high level of residual risk of CVD events and microvascular complications among patients with dyslipidemia receiving therapy for high levels of LDL cholesterol and for diabetes in accordance with current standards of care.

AB - Despite achieving targets for low-density lipoprotein (LDL) cholesterol, blood pressure, and glycemia in accordance with current standards of care, patients with dyslipidemia remain at high residual risk of vascular events. Atherogenic dyslipidemia, characterized by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol, often with elevated apolipoprotein B and non-HDL cholesterol, is common in patients with established cardiovascular disease (CVD), type 2 diabetes mellitus, or metabolic syndrome and contributes to both macrovascular and microvascular residual risk. However, atherogenic dyslipidemia is largely underdiagnosed and undertreated in clinical practice. The Residual Risk Reduction Initiative (R3i) was established to address this highly relevant clinical issue. The aims of this position paper are (1) to highlight evidence that atherogenic dyslipidemia is associated with residual macrovascular and microvascular risk in patients at high risk for CVD, despite current standards of care for dyslipidemia and diabetes; and (2) to recommend therapeutic intervention for reducing this residual vascular risk supported by evidence and expert consensus. Lifestyle modification with nutrition and exercise is an important, effective, and underutilized first step in reducing residual vascular risk. Therapeutic intervention aimed at achievement of all lipid targets is also often required. Combination lipid-modifying therapy, with the addition of niacin, a fibrate, or omega-3 fatty acids to statin therapy, increases the probability of achieving all lipid goals. Outcomes studies are in progress to evaluate whether these combination treatment strategies translate to a clinical benefit greater than that achieved with statins alone. The R3i highlights the need to address with lifestyle and/or pharmacotherapy the high level of residual risk of CVD events and microvascular complications among patients with dyslipidemia receiving therapy for high levels of LDL cholesterol and for diabetes in accordance with current standards of care.

UR - http://www.scopus.com/inward/record.url?scp=56349154187&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2008.10.002

DO - 10.1016/j.amjcard.2008.10.002

M3 - Article

VL - 102

SP - 1K-34K

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 10 SUPPL.

ER -